If You Invested in Grace Therapeutics, Inc (GRCE)

Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage biopharma company in the healthcare sector focused on rare and orphan diseases. According to the company’s public disclosures, Grace Therapeutics develops drug candidates that use novel drug delivery technologies intended to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. The company’s lead clinical asset is GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in patients with aneurysmal subarachnoid hemorrhage (aSAH), a rare and life‑threatening type of stroke.

Grace Therapeutics states that its lead clinical assets have each been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), which generally provides seven years of marketing exclusivity in the United States post‑launch, alongside an intellectual property estate that includes over 40 granted and pending patents. For GTx‑104, the company reports a multi‑layered patent position that includes composition patents extending to 2037 and a method‑of‑use patent covering the IV dosing regimen, with protection reported to extend to 2043.

Core focus: GTx‑104 for aneurysmal subarachnoid hemorrhage

GTx‑104 is described in company press releases and SEC filings as a clinical-stage, novel, injectable formulation of nimodipine designed for IV infusion via a standard peripheral IV line. The formulation uses a nanoparticle technology that facilitates an aqueous formulation of otherwise insoluble nimodipine. Grace Therapeutics reports that GTx‑104 is being developed to address significant unmet medical needs in patients with aSAH, a condition characterized by bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, often caused by rupture of a brain aneurysm.

According to the company, GTx‑104 aims to provide convenient IV delivery of nimodipine in the intensive care unit (ICU), with the potential to eliminate the need for nasogastric tube administration in unconscious or dysphagic patients. Company disclosures state that IV administration of GTx‑104 has the potential to lower food effects, reduce drug‑to‑drug interactions, and eliminate certain dosing errors associated with oral nimodipine. Grace Therapeutics also reports that GTx‑104 may help better manage hypotension in aSAH patients.

Grace Therapeutics has reported results from its pivotal Phase 3 STRIVE‑ON safety trial (NCT05995405), a prospective, randomized, open‑label trial comparing GTx‑104 with oral nimodipine in hospitalized aSAH patients. The company states that the trial met its primary endpoint, which was the number of patients with at least one episode of clinically significant hypotension reasonably considered to be caused by the drug. Company communications describe a reduction in such hypotensive events in patients receiving GTx‑104 compared with oral nimodipine, as well as secondary measures that favored or were comparable to GTx‑104, including relative dose intensity, functional outcomes at 90 days, and ICU resource utilization. Adverse events were reported as comparable between treatment arms, with no new safety issues identified and no deaths determined to be related to GTx‑104 or oral nimodipine.

Regulatory status and NDA submission

Grace Therapeutics has publicly announced the submission of a New Drug Application (NDA) to the FDA seeking approval of GTx‑104 for the treatment of patients with aSAH. The company reports that the NDA is supported by a comprehensive data package, including positive results from the Phase 3 STRIVE‑ON safety trial. Subsequent disclosures state that, on August 22, 2025, the FDA accepted the NDA for formal review and established a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026 for its review of the submission.

Grace Therapeutics notes that FDA acceptance of the NDA for review has implications for certain financing arrangements, including common stock warrants issued in prior private placements that may be exercisable based on NDA milestones. The company also highlights that GTx‑104 has received Orphan Drug Designation, which generally provides seven years of U.S. marketing exclusivity upon approval, and that its U.S. and international patent estate is intended to protect the market value of GTx‑104 beyond the orphan exclusivity period.

Intellectual property and patent estate

In its news releases and Form 8‑K filings, Grace Therapeutics describes a multi‑layered intellectual property estate for GTx‑104. This includes multiple patents on the composition of the nimodipine formulation and at least one method‑of‑use patent covering the IV dosing regimen used in the STRIVE‑ON trial. The company reports that composition patents provide protection into 2037, while the method‑of‑use patent extends coverage to 2043. Grace Therapeutics states that, if GTx‑104 is approved by the FDA, these patents, together with orphan drug exclusivity, are expected to provide extended protection for its proprietary work on GTx‑104.

Additional pipeline assets: GTx‑102 and GTx‑101

Beyond GTx‑104, Grace Therapeutics describes an asset portfolio that includes GTx‑102 and GTx‑101, both targeting rare or underserved conditions.

• GTx‑102 is described as a novel, concentrated oral‑mucosal spray of betamethasone intended to improve neurological symptoms of Ataxia‑Telangiectasia (A‑T), for which the company notes there are currently no FDA‑approved therapies. GTx‑102 is characterized as a stable, concentrated oral spray formulation of the glucocorticosteroid betamethasone, designed to be sprayed over the tongue and rapidly absorbed. Grace Therapeutics reports that it has received written responses from the FDA at an End of Phase 1 meeting, including guidance on the design of a single pivotal efficacy and safety trial and the neurological assessment scale for the primary endpoint that could, with appropriate confirmatory evidence, support an NDA. The company also states that further development of GTx‑102 has been deprioritized in favor of focusing on GTx‑104, and that licensing or sale of GTx‑102 is a possibility.
• GTx‑101 is described as a non‑narcotic, topical bio‑adhesive film‑forming bupivacaine spray designed to ease symptoms in patients with postherpetic neuralgia (PHN). According to company disclosures, GTx‑101 is administered via a metered‑dose spray that forms a thin bio‑adhesive topical film on the skin, enabling touch‑free, non‑greasy application. The product is described as being supplied in portable 30 ml plastic bottles. Grace Therapeutics states that, unlike oral gabapentin and lidocaine patches used for PHN, the biphasic delivery mechanism of GTx‑101 has the potential for rapid onset of action and continuous pain relief for up to eight hours, and that no skin sensitivity was reported in a Phase 1 trial. As with GTx‑102, the company reports that development of GTx‑101 has been deprioritized while resources are focused on GTx‑104, and that it may license or sell GTx‑101.

Therapeutic area: aneurysmal subarachnoid hemorrhage (aSAH)

Grace Therapeutics provides background on the condition targeted by its lead program. aSAH is described as bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is identified as the rupture of an aneurysm in the brain. The company characterizes aSAH as a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital‑treated patients. Company statements emphasize that the standard of care for aSAH has not seen meaningful innovation in nearly 40 years, and that GTx‑104 is being developed as a potential new option in this setting.

Clinical experience and tolerability of GTx‑104

Across multiple press releases, Grace Therapeutics reports that GTx‑104 has been administered in over 200 patients and healthy volunteers. The company states that the product was well tolerated and that GTx‑104 demonstrated significantly lower inter‑ and intra‑subject pharmacokinetic variability compared to oral nimodipine. In the STRIVE‑ON trial, the company notes that adverse events were comparable between the GTx‑104 and oral nimodipine arms, with no new safety signals identified and no deaths determined to be related to either treatment.

Corporate profile and governance

Grace Therapeutics, Inc. is incorporated in the State of Delaware, as disclosed in SEC filings. The company’s principal offices are located in Princeton, New Jersey. Grace Therapeutics’ common stock trades on Nasdaq under the symbol GRCE, and the company files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q, 8‑K, and proxy statements.

In its definitive proxy statement, Grace Therapeutics outlines its annual meeting process, board composition, and standard governance matters such as director elections, advisory votes on executive compensation, and ratification of its independent registered public accounting firm. The proxy statement also notes that the company was formerly known as Acasti Pharma Inc. and that references to “Grace Therapeutics” or the “Company” include Grace Therapeutics, Inc. and its consolidated subsidiary.

Business model and development strategy

Based on its public statements, Grace Therapeutics’ business model centers on late-stage drug development for rare and orphan indications using proprietary drug delivery technologies. The company emphasizes leveraging these technologies to modify existing active pharmaceutical ingredients, such as nimodipine, betamethasone, and bupivacaine, with the goal of improving clinical performance and patient convenience. Its current strategy, as described in recent communications, prioritizes advancing GTx‑104 through the regulatory process, while GTx‑102 and GTx‑101 remain in the portfolio but with development deprioritized and potential partnering or out‑licensing under consideration.

Frequently asked questions (FAQ)

The following FAQs summarize key points about Grace Therapeutics, Inc. (GRCE) based solely on its public disclosures.